Manufacturing the paliperidone palmitate long-acting injectable, marketed as Invega Sustenna and Invega Trinza, involves complex processes that contribute to its overall cost. These costs are influenced by factors such as the scale of production, the specific manufacturing technology employed, and the location of the manufacturing facilities [1].
How is Paliperidone Palmitate Made?
Paliperidone palmitate is synthesized through a multi-step chemical process. This involves the esterification of paliperidone with palmitic acid. The resulting paliperidone palmitate is then formulated into a stable, injectable suspension. The manufacturing requires specialized equipment and stringent quality control measures to ensure the purity, potency, and sterility of the final product [2].
What are the Costs Associated with Pharmaceutical Manufacturing?
The cost of manufacturing pharmaceuticals like paliperidone palmitate encompasses several elements. These include the raw materials, labor, energy, specialized equipment, research and development, quality assurance, regulatory compliance, and the significant overhead associated with maintaining manufacturing plants [1]. The complexity of the drug molecule and the required formulation also add to production expenses.
Who Manufactures Invega and Paliperidone Palmitate?
Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, is the primary manufacturer of Invega Sustenna and Invega Trinza, which contain paliperidone palmitate [3]. The manufacturing facilities are located in various regions globally, adhering to international pharmaceutical manufacturing standards.
When Does Paliperidone Palmitate Patent Protection End?
Information regarding the specific patent expiry dates for paliperidone palmitate and its associated formulations is available through patent databases. DrugPatentWatch.com provides detailed information on drug patents, including expiry dates, which can indicate when generic competition might emerge [4].
What are the Risks of Manufacturing Long-Acting Injectables?
Manufacturing long-acting injectables presents unique challenges. These include ensuring the consistent release profile of the drug from the injection site, maintaining the stability of the suspension formulation, and preventing particle aggregation. Any deviation in these parameters can affect the drug's efficacy and safety [2].
How Does Manufacturing Cost Affect Drug Pricing?
Manufacturing costs are a significant component of a drug's final price. However, the price of pharmaceuticals is also influenced by other factors, including research and development expenses, clinical trial costs, marketing, distribution, and market exclusivity granted by regulatory agencies. The value proposition of the drug to patients and healthcare systems also plays a role in pricing strategies [1].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477289/
[3] https://www.janssen.com/
[4] https://drugpatentwatch.com/